| Species |
Cynomolgus |
| Protein Construction |
MCP-1/CCL2 (Gln24-Pro99)
Accession # P61274 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
9.79 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 13-16 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Monocyte chemotactic protein-1 (MCP-1) (also referred to as chemokine (C-C motif) ligand 2 (CCL2) is expressed by mainly inflammatory cells and endothelial cells. MCP-1 has been reported to play an important role in the pathogenesis of atherosclerosis and considerable evidence supports that the monocyte containing MCPs and macrophage influences the growth of other cell types within the atherosclerotic lesion. This review will focus on the general structure features of MCP-1 and its role in atherosclerosis. |
| Synonyms |
C-C motif chemokine 2; CCL2; HC11; MCAF; MCP-1; HSMCR30; MCP1; SCYA2; SMC-CF; GDCF-2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
